Glenmark Pharma share price up 2% on rolling out Lacosamide oral solution

The uptick in Glenmark Pharmaceuticals share price came after the company announced the launch of Lacosamide Oral Solution, 10 mg/mL

drugs, pharma sector
SI Reporter New Delhi
2 min read Last Updated : Dec 16 2024 | 11:57 AM IST
Glenmark Pharmaceuticals share price: Pharmaceutical major Glenmark Pharmaceuticals shares rose up to 2.27 per cent to hit an intraday high of Rs 1,551.75 per share on Monday, December 16, 2024.
 
The uptick in Glenmark Pharmaceuticals share price came after the company announced the launch of Lacosamide Oral Solution, 10 mg/mL. Lacosamide is a medication used to treat and prevent seizures, also known as convulsions, in individuals with epilepsy.
 
“We are excited to announce the launch of Lacosamide Oral Solution, 10 mg/mL, strengthening our commitment to bring to market quality and affordable alternatives for patients,” said Marc Kikuchi, president and business head, North America of Glenmark Pharmaceuticals.
 
Glenmark Pharmaceuticals’ Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc., Glenmark Pharma said in a statement.
 
The Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57 million, according to IQVIATM sales data for the 12-month period ending October 2024.
 
About Glenmark Pharmaceuticals 
 
Glenmark Pharmaceuticals is a global, research-driven pharmaceutical company with expertise in Branded, Generics, and OTC segments. The company specialises in key therapeutic areas, including respiratory, dermatology, and oncology.
 
Glenmark Pharmaceuticals’ US portfolio features 201 approved products and 51 abbreviated new drug approvals (ANDAs) currently awaiting FDA approval. Beyond its internal development, Glenmark actively seeks external partnerships to strengthen and expand its pipeline and portfolio.
 
The company boasts 11 state-of-the-art manufacturing facilities across four continents and has operations in more than 80 countries.
 
The market capitalisation of Glenmark Pharmaceuticals is Rs 43,31.47 crore, according to BSE. 
 
Glenmark Pharmaceuticals shares’ 52-week high is Rs 1,830.05 per share, while its 52-week low is Rs 766.65 apiece.
 
At 11:40 AM, Glenmark Pharmaceuticals shares were trading 1.17 per cent higher ay Rs 1,534.95 apiece. In comparison, BSE Sensex was trading 0.51 per cent lower at 81.710.75 levels.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Buzzing stocksBSE NSENSE Nifty50 benchmark indexIndian stock exchangesMarkets Sensex NiftyMARKETS TODAYGlenmark PharmaceuticalsIndian stock marketsBSE SensexNifty50

First Published: Dec 16 2024 | 11:53 AM IST

Next Story